GDRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

192.82M

-2.9%

0.035

+250%

193.75M

-4.54%

0.031

+56.65%

200.59M

-1.22%

0.028

-8.33%

Estimates Revision

The market is revising Downward the revenue expectations for GoodRx Holdings, Inc. (GDRX) for FY2025, with the revenue forecasts being adjusted by -0.52% over the past three months. During the same period, the stock price has changed by -35.93%.

Revenue Estimates for FY2025

Revise Downward

-0.52%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-19.35%

In Past 3 Month

Stock Price

Go Down

-35.93%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast GDRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDRX is 4.97 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

4 Hold

1 Sell

Moderate Buy

Current: 2.710

Low

3.00

Averages

4.97

High

7.00

Current: 2.710

Low

3.00

Averages

4.97

High

7.00

Barclays

Underweight

initiated

2025-12-08

Reason

Barclays

Price Target

2025-12-08

initiated

Underweight

Reason

Barclays initiated coverage of GoodRx with an Underweight rating and $3 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.

BofA

Underperform

maintain

2025-11-17

Reason

BofA

Price Target

2025-11-17

maintain

Underperform

Reason

BofA lowered the firm's price target on GoodRx to $3 from $3.40 and keeps an Underperform rating on the shares after the company announced two initiatives for its weight loss offering. BofA sees the announcement positively as the collaboration builds on GoodRx's existing partnership with Novo Nordisk and further expands the subscription offering, the firm told investors. BofA acknowledged the progress that GoodRx is making to expand partnerships but maintained its Underperform rating given broader headwinds from pharmacy closures and reimbursement changes in the pharmacy ecosystem.

JPMorgan

Lisa Gill

Overweight

downgrade

$6 -> $5

2025-11-11

Reason

JPMorgan

Lisa Gill

Price Target

$6 -> $5

2025-11-11

downgrade

Overweight

Reason

JPMorgan analyst Lisa Gill lowered the firm's price target on GoodRx to $5 from $6 and keeps an Overweight rating on the shares. The firm updated the company's model.

TD Cowen

Buy

downgrade

$7 -> $6

2025-11-10

Reason

TD Cowen

Price Target

$7 -> $6

2025-11-10

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on GoodRx to $6 from $7 and keeps a Buy rating on the shares. The firm said some new offerings show promise and company's role in Cigna's new PBM model is potential positive, but material impact unlikely until at least 2027. That said, valuation overly discounts the weaker near-term outlook.

Mizuho

Neutral

downgrade

$5 -> $4

2025-11-06

Reason

Mizuho

Price Target

$5 -> $4

2025-11-06

downgrade

Neutral

Reason

Mizuho lowered the firm's price target on GoodRx to $4 from $5 and keeps a Neutral rating on the shares.

UBS

Kevin Caliendo

Neutral

downgrade

2025-11-06

Reason

UBS

Kevin Caliendo

Price Target

2025-11-06

downgrade

Neutral

Reason

UBS analyst Kevin Caliendo lowered the firm's price target on GoodRx to $4 from $4.25 and keeps a Neutral rating on the shares.

Valuation Metrics

The current forward P/E ratio for GoodRx Holdings Inc (GDRX.O) is 18.80, compared to its 5-year average forward P/E of 113.20. For a more detailed relative valuation and DCF analysis to assess GoodRx Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

113.20

Current PE

18.80

Overvalued PE

761.48

Undervalued PE

-535.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

22.14

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

43.48

Undervalued EV/EBITDA

0.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.71

Current PS

0.00

Overvalued PS

13.58

Undervalued PS

-0.16

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 1160% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GDRX News & Events

Events Timeline

No data

News

9.0

12-04MarketWatch

Wegovy Prices Are Decreasing, Yet They Remain 'Significantly Varied' and Confusing

3.0

11-28NASDAQ.COM

HIMS vs. GDRX: Which Health Stock Presents More Potential for Growth?

5.0

11-17Benzinga

Novo Nordisk Focuses on Cost-Effectiveness in Response to Increasing Competition

People Also Watch

Frequently Asked Questions

What is GoodRx Holdings Inc (GDRX) stock price today?

The current price of GDRX is 2.71 USD — it has decreased -3.9 % in the last trading day.

What is GoodRx Holdings Inc (GDRX)'s business?

GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordability solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications.

What is the price predicton of GDRX Stock?

What is GoodRx Holdings Inc (GDRX)'s revenue for the last quarter?

GoodRx Holdings Inc revenue for the last quarter amounts to 196.03M USD, increased 0.40 % YoY.

What is GoodRx Holdings Inc (GDRX)'s earnings per share (EPS) for the last quarter?

GoodRx Holdings Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for GoodRx Holdings Inc (GDRX)'s fundamentals?

How many employees does GoodRx Holdings Inc (GDRX). have?

GoodRx Holdings Inc (GDRX) has 738 emplpoyees as of December 16 2025.

What is GoodRx Holdings Inc (GDRX) market cap?

Today GDRX has the market capitalization of 919.86M USD.